Search Results - "Martínez Ortega, E."

Thermal pre-treatment: Getting some insights on the formation of recalcitrant compounds and their effects on anaerobic digestion by Ortega-Martínez, E., Chamy, R., Jeison, D.

“…Thermal hydrolysis is a common pre-treatment, used before anaerobic digestion processes, to enhance the hydrolysis rate. However, formation of inhibitory…”
Get full text

Potential use of Bacillus thuringiensis bacteriocins to control antibiotic-resistant bacteria associated with mastitis in dairy goats by Gutiérrez-Chávez, A. J, Martínez-Ortega, E. A, Valencia-Posadas, M, León-Galván, M. F, de la Fuente-Salcido, N. M, Bideshi, D. K, Barboza-Corona, J. E

“…Mastitis caused by microbial infections in dairy goats reduces milk yield, modifies milk composition, and potentially contributes to morbidity in herds and…”
Get full text

La investigacion en marketing a traves de las tesis doctorales Españolas by Ortega Martínez, E

“…Doctoral dissertations provide a relevant contribution in a field. The general purpose of the dissertation research is to demonstrate research competence and…”
Get full text

Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients by Sánchez-Muñoz, Alfonso, Dueñas-García, R, Jaén-Morago, A, Carrasco, E, Chacón, I, García-Tapiador, A M, Ortega-Granados, A L, Martínez-Ortega, E, Ribelles, N, Fernández-Navarro, M, de la Torre-Cabrera, C, Dueñas, B, Rueda, A I, Martínez, J, Tortosa, C Ramírez, Martín-Salvago, M D, Sánchez-Rovira, P

“…To evaluate the pathologic complete response (pCR) rate of a combination of epirubicin (E) and cyclophosphamide (C) followed by paclitaxel (P) and gemcitabine…”
Get full text

Impact of milling, enzyme addition, and steam explosion on the solid waste biomethanation of an olive oil production plant by Donoso-Bravo, Andres, Ortega-Martinez, E, Ruiz-Filippi, G

“…Anaerobic digestion is a consolidated bioprocess which can be further enhanced by incorporating an upstream pretreatment unit. The olive oil production…”
Get full text

1741P Atezolizumab (ATZ) with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA): A multicentre, single-arm phase II trial by De Velasco Oria, G.A., García-Carbonero, I., Esteban-Gonzalez, E., Pinto, A., Lorente, D., Gómez de Liaño, A., Martínez Ortega, E., Jimenez Colomo, L., Puente, J., Gonzalez, I., Fernández, O., Anguera, G.

Get full text

Syntomoza Amaliae, a New Species of Moth-Fly (Diptera, Psychodidae) from Nicaragua by Collantes, F., Martínez-Ortega, E.

“…A new species of Psychodidae, Syntomoza amaliae is described from Nicaragua and compared to all the type material of this genus. Besides head and wing…”
Get full text

Familial hypercholesterolemia in children and adolescents: Management and control by sex. A longitudinal analysis from the national dyslipidemia registry of the Spanish atherosclerosis society by Viñals, C., Jiménez, A., Yago, G., Domenech, M., Plana, N., Ortega-Martínez De Victoria, E.

Get full text

Revisión de la colección Nájera de Flebotomos (Diptera, Psychodidae) depositada en el Museo Nacional de Ciencias Naturales de Madrid by León Sanz, C. M., Collantes, F., Martínez-Ortega, E.

“…No disponible…”
Get full text

Rectificación a la primera cita de Flebotomos (Diptera, Psychodidae) en la Península Ibérica by León Sanz, C. M., Collantes, F., Martínez-Ortega, E.

“…No disponible…”
Get full text

Clinical predictors of positive genetic testing in heterozygous familial hypercholesterolemia by Benedí, V. Marco, Cenarro, A., Ortega-Martínez De Victoria, E., Plana, N., Pinto, X., Sánchez-Hernández, R., Vallejo-Vaz, A., Civeira, F.

Get full text

Neoadjuvant chemotherapy with a dose-dense sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer. Correlation between pathologic complete response (pCR) and biologic markers by Sanchez, A., Dueñas-García, R., Jaén-Morago, A., Chacón, I., García-Tapiador, A., Martínez-Ortega, E., de la Torre-Cabrera, C., Dueñas, B., Ribelles, N., Sánchez-Rovira, P.

“…Abstract only 595 Background: To evaluate the efficacy, measured as pCR, and safety of a noncross-resistant sequential and dose- dense schedule as neoadjuvant…”
Get full text

Assessment of pathological complete response (pCR) to neoadjuvant dose-dense chemotherapy in HER2+ patients with locally advanced breast cancer (LABC) treated with trastuzumab (T) compared with HER2+ and HER2- patients treated without T by Sanchez-Muñoz, A., García-Tapiador, A. M., Dueñas-García, R., Jaén-Morago, A., Martínez-Ortega, E., Fernández-Navarro, M., de la Torre-Cabrera, C., Dueñas, B., Morales, F., Sánchez-Rovira, P.

“…Abstract only 11057 Purpose: To identify Her2+expression as predictive factor for pCR to T in pts with LABC treated with neoadjuvant chemotherapy. Methods: A…”
Get full text

Syntomoza matagalpensis, a New Moth-Fly from Nicaragua (Diptera, Psychodidae) by Collantes, F., Martinez-Ortega, E

“…A new species of Psychodidae, Syntomoza matagalpensis from Nicaragua is described. Morphology of both male and female and notes on their biology are offered…”
Get full text

954P - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz) by Valderrama, B.P., Perez Ramirez, S., Rodriguez-Vida, A., González del Alba, A., Mendez Vidal, M.J., Vazquez Estevez, S., Martinez Ortega, E., Virizuela, J.A., Fernández Calvo, O., Hernández Jorge, A., Vazquez Mazon, F.J., Gonzalez Gragera, M.B., Campayo, M., Etxaniz Ulazia, O., Almagro Casado, E., Sereno Moyano, M., Abad Villar, M.T., Suarez Rodriguez, C., Gallardo Diaz, E., Arranz Arija, J.A.

“…IMDC classifies patients (pt) with mRCC in favorable, intermediate or poor-risk (FR, IR, PR). IR pt having 1 vs 2 unfavorable factors (IR1 vs IR2) treated with…”
Get full text

954PSPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz) by Valderrama, B P, Perez Ramirez, S, Rodriguez-Vida, A, González del Alba, A, Mendez Vidal, M J, Vazquez Estevez, S, Martinez Ortega, E, Virizuela, J A, Fernández Calvo, O, Hernández Jorge, A, Vazquez Mazon, F J, Gonzalez Gragera, M B, Campayo, M, Etxaniz Ulazia, O, Almagro Casado, E, Sereno Moyano, M, Abad Villar, M T, Suarez Rodriguez, C, Gallardo Diaz, E, Arranz Arija, J A

“…Abstract Background IMDC classifies patients (pt) with mRCC in favorable, intermediate or poor-risk (FR, IR, PR). IR pt having 1 vs 2 unfavorable factors (IR1…”
Get full text

Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from the prospective PROREPAIR-B study by Cattrini, C., Laorden, N Romero, Castro, E., García-Carbonero, I., Piulats, J.M., Puente, J., Valderrama, B.P., Guzman, J C Villa, Billalabeitia, E Gonzalez, Barrera, R Morales, Mejorada, R Lozano, Luque, R., Ortega, E Martinez, Arija, J A Arranz, Diaz, E Gallardo, Marin, A Pinto, Casado, E Almagro, Vidal, M J Mendez, Hidalgo, D Olmos, Lorente, D.

Get full text

880P - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from the prospective PROREPAIR-B study by Cattrini, C., Laorden, N Romero, Castro, E., García-Carbonero, I., Piulats, J.M., Puente, J., Valderrama, B.P., Guzman, J C Villa, Billalabeitia, E Gonzalez, Barrera, R Morales, Mejorada, R Lozano, Luque, R., Ortega, E Martinez, Arija, J A Arranz, Diaz, E Gallardo, Marin, A Pinto, Casado, E Almagro, Vidal, M J Mendez, Hidalgo, D Olmos, Lorente, D.

“…Abiraterone (Abi), enzalutamide (Enz) and docetaxel (Doc) are all approved first-line (1L) treatment options for mCRPC. However, the optimal treatment sequence…”
Get full text

880PImpact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from the prospective PROREPAIR-B study by Cattrini, C, Laorden, N Romero, Castro, E, García-Carbonero, I, Piulats, J M, Puente, J, Valderrama, B P, Guzman, J C Villa, Billalabeitia, E Gonzalez, Barrera, R Morales, Mejorada, R Lozano, Luque, R, Ortega, E Martinez, Arija, J A Arranz, Diaz, E Gallardo, Marin, A Pinto, Casado, E Almagro, Vidal, M J Mendez, Hidalgo, D Olmos, Lorente, D

“…Abstract Background Abiraterone (Abi), enzalutamide (Enz) and docetaxel (Doc) are all approved first-line (1L) treatment options for mCRPC. However, the…”
Get full text

SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz) by Valderrama, B.P., Perez Ramirez, S., Rodriguez-Vida, A., González del Alba, A., Mendez Vidal, M.J., Vazquez Estevez, S., Martinez Ortega, E., Virizuela, J.A., Fernández Calvo, O., Hernández Jorge, A., Vazquez Mazon, F.J., Gonzalez Gragera, M.B., Campayo, M., Etxaniz Ulazia, O., Almagro Casado, E., Sereno Moyano, M., Abad Villar, M.T., Suarez Rodriguez, C., Gallardo Diaz, E., Arranz Arija, J.A.

Get full text